Literature DB >> 21345793

G alpha(q) signal in osteoblasts is inhibitory to the osteoanabolic action of parathyroid hormone.

Naoshi Ogata1, Yusuke Shinoda, Nina Wettschureck, Stefan Offermanns, Shu Takeda, Kozo Nakamura, Gino V Segre, Ung-il Chung, Hiroshi Kawaguchi.   

Abstract

This study examined the role of the Gα(q) signal constituted by Gα(q) and Gα(11) (encoded by Gnα(q) and Gnα(11), respectively), a major intracellular pathway of parathyroid hormone (PTH), in the PTH osteoanabolic action by the gain- and loss-of-function analyses. Transgenic mice with osteoblast-specific overexpression of the constitutively active Gnα(q) gene under the control of 2.3-kb type I collagen α1 chain (Col1a1) promoter exhibited osteopenia with decreased bone formation parameters and did not respond to the daily PTH treatment. We then established osteoblast-specific Gnα(q) and Gnα(11) double-knock-out (cDKO) mice by crossing the 2.3-kb Col1a1 promoter-Cre recombinase transgenic mice and those with Gnα(q) gene flanked with loxP and global ablation of Gnα(11) (Col1a1-Cre(+/-);Gna(q)(fl/fl);Gna(11)(-/-)) and found that the cDKO and single knock-out littermates of Gnα(q) or Gnα(11) exhibited normal bone volume and turnover under physiological conditions. With a daily injection of PTH, however, the cDKO mice, but not the single knock-out mice, showed higher bone volume and turnover than the wild-type littermates. Cultures of primary osteoblasts derived from cDKO and wild-type littermates confirmed enhancement of the PTH osteoanabolic action by the Gα(q) signal deficiency in a cell-autonomous mechanism, in association with the membrane translocation of protein kinase Cδ. This enhancement was reproduced by overexpression of regulator of G protein signaling-2, a Gα(q) signal inhibitor, in osteoblastic MC3T3-E1 cells. Hence, the Gα(q) signal plays an inhibitory role in the PTH osteoanabolic action, suggesting that its suppression may lead to a novel treatment in combination with PTH against osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21345793      PMCID: PMC3075717          DOI: 10.1074/jbc.M110.200196

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  The regulator of G protein signaling family.

Authors:  L De Vries; B Zheng; T Fischer; E Elenko; M G Farquhar
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 2.  Gs signaling in osteoblasts and hematopoietic stem cells.

Authors:  Henry M Kronenberg
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

Review 3.  Parathyroid hormone-dependent signaling pathways regulating genes in bone cells.

Authors:  John T Swarthout; Richard C D'Alonzo; Nagarajan Selvamurugan; Nicola C Partridge
Journal:  Gene       Date:  2002-01-09       Impact factor: 3.688

4.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes.

Authors:  N Wettschureck; H Rütten; A Zywietz; D Gehring; T M Wilkie; J Chen; K R Chien; S Offermanns
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

Review 5.  GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins.

Authors:  E M Ross; T M Wilkie
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

6.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

Review 7.  Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting.

Authors:  L S Weinstein; S Yu; D R Warner; J Liu
Journal:  Endocr Rev       Date:  2001-10       Impact factor: 19.871

Review 8.  Mouse models to study G-protein-mediated signaling.

Authors:  Nina Wettschureck; Alexandra Moers; Stefan Offermanns
Journal:  Pharmacol Ther       Date:  2004-01       Impact factor: 12.310

9.  Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast.

Authors:  Romain Dacquin; Michael Starbuck; Thorsten Schinke; Gérard Karsenty
Journal:  Dev Dyn       Date:  2002-06       Impact factor: 3.780

10.  Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone.

Authors:  Daniel D Bikle; Takeshi Sakata; Colin Leary; Hashem Elalieh; David Ginzinger; Clifford J Rosen; Wesley Beamer; Sharmila Majumdar; Bernard P Halloran
Journal:  J Bone Miner Res       Date:  2002-09       Impact factor: 6.741

View more
  10 in total

Review 1.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

Review 2.  Parathyroid hormone: anabolic and catabolic actions on the skeleton.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Curr Opin Pharmacol       Date:  2015-04-05       Impact factor: 5.547

Review 3.  Heterotrimeric G proteins in the control of parathyroid hormone actions.

Authors:  Murat Bastepe; Serap Turan; Qing He
Journal:  J Mol Endocrinol       Date:  2017-05       Impact factor: 5.098

4.  Skeletal defects in Osterix-Cre transgenic mice.

Authors:  Wei Huang; Bjorn R Olsen
Journal:  Transgenic Res       Date:  2014-08-20       Impact factor: 2.788

5.  Inactivation of Osteoblast PKC Signaling Reduces Cortical Bone Mass and Density and Aggravates Renal Osteodystrophy in Mice with Chronic Kidney Disease on High Phosphate Diet.

Authors:  Ariane Zaloszyc; Philippe Choquet; Amira Sayeh; Maria Bartosova; Betti Schaefer; Ulrike Huegel; Gaëlle Aubertin-Kirch; Christopher Healy; François Severac; Sébastien Rizzo; Georges Boivin; Franz Schaefer; Michel Fischbach; Justine Bacchetta; Seiamak Bahram; Claus Peter Schmitt
Journal:  Int J Mol Sci       Date:  2022-06-08       Impact factor: 6.208

6.  Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines.

Authors:  Tonio Pera; Deepak A Deshpande; Michael Ippolito; Bin Wang; Adelina Gavrila; James V Michael; Ajay P Nayak; Eric Tompkins; Eleni Farrell; Wesley K Kroeze; Bryan L Roth; Reynold A Panettieri; Jeffrey L Benovic; Steven S An; Nickolai O Dulin; Raymond B Penn
Journal:  FASEB J       Date:  2018-01-04       Impact factor: 5.834

7.  Ixazomib enhances parathyroid hormone-induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor.

Authors:  Yanmei Yang; Hong Lei; Ya-Wei Qiang; Bin Wang
Journal:  Mol Biol Cell       Date:  2017-05-11       Impact factor: 4.138

Review 8.  PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases.

Authors:  Yanmei Yang; Bin Wang
Journal:  Int J Endocrinol       Date:  2018-07-29       Impact factor: 3.257

9.  Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide.

Authors:  Karim Sahbani; Christopher P Cardozo; William A Bauman; Hesham A Tawfeek
Journal:  Physiol Rep       Date:  2019-10

10.  Pasteurella multocida toxin prevents osteoblast differentiation by transactivation of the MAP-kinase cascade via the Gα(q/11)--p63RhoGEF--RhoA axis.

Authors:  Peter Siegert; Gudula Schmidt; Panagiotis Papatheodorou; Thomas Wieland; Klaus Aktories; Joachim H C Orth
Journal:  PLoS Pathog       Date:  2013-05-16       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.